best-in-class aim, with high safety & Tolerability profile
Through Providence’s World-Class-Scientific team, we created our first fully Made-in-Canada mRNA vaccine, PTX-COVID19-B in April 2020 at the very beginning of the global pandemic.
Through our Phase 1 Human Clinical Trial results, our vaccine has shown a very favourable response with a high level of neutralizing antibodies, while showing to be safe and effective.
Status: Currently in Phase 2 Human Clinical Trial August 2021
Strategy: Generate potent neutralizing antibodies to prevent infection and promote strong immunity.
Providence’s PTX-COVID19-B aims to be the Best-In-Class, with high safety and tolerability profile.